Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Enterocolitis, Pseudomembranous

• Bezlotoxumab Versus FMT for Multiple Recurrent CDI
• A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)
• Bezlotoxumab Efficacy and Tolerability in Cancer Patient
• Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection
• Treatment of Mild-moderate Clostridium Difficile Infection (CDI)
• Efficacy and Safety of Teicoplanin in CDAD
• Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
• Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
• PMT for Severe-CDI
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)
• Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
• Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection
• ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI
• Fecal Transplantation for Primary Clostridium Difficile Infection
• Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection
• Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
• Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
• Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
• ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
• Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
• Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
• The ICON Study: Outcomes After FMT for Patients With IBD and CDI
• Screening to Prophylax Against Clostridium Difficile Infection -
• Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
• MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
• SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
• A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
• Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection
• A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
• Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
• FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment
• Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection
• Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
• Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection
• Freeze-dried, Capsulized FMT for RCDI
• IMT for Primary Clostridium Difficile Infection
• FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
• Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection
• Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
• Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection
• Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum
• The Impact of Proton Pump Inhibitors on the Fecal Microbiome
• Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin
• A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
• A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
• Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
• Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin
• Study of CB-183,315 in Participants With Clostridium Difficile Infection
• Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections
• Extended Treatment With Vancomycin for Clostridium Difficile Colitis
• A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea
• A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
• Addition of Lactobacillus to Metronidazole in Treatment of CDAD
• Response of Clostridium Difficile Infection to Metronidazole Therapy
• Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
• A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea
• Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
• The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study
• A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
• A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea